Your browser version may not work well with NCBI's Web applications. More information here...
1: Crit Care. 2008;12(2):139. Epub 2008 Apr 24.
Related Articles, Links
Click here to read
Comment on:
Protein C as a surrogate end-point for clinical trials of sepsis.

Liu KD, Matthay MA.

Divisions of Nephrology and Critical Care Medicine, Department of Medicine, University of California, 521 Parnassus Ave, C443, San Francisco, CA 94143, USA.

Identification of good surrogate end-points can greatly facilitate the design of clinical trials. Using data from PROWESS and ENHANCE, Shorr and colleagues explore the potential value of several plasma biomarkers for treatment trials of activated protein C for severe sepsis. Based on the framework proposed by Vasan, they tested the utility of several factors (protein C, interleukin-6, antithrombin III, prothrombin time, protein S, and d-dimers) as type 0, 1 and 2 biomarkers. Only protein C had acceptable performance characteristics as a type 2 biomarker, or surrogate end-point. The utility of protein C as a surrogate end-point for studies of severe sepsis must be validated in future prospective studies.

Publication Types:
PMID: 18492215 [PubMed - indexed for MEDLINE]

PMCID: PMC2447596